Traws Pharma Company Insiders
| TRAW Stock | 5.02 0.31 5.82% |
Traws Pharma employs about 17 people. The company is managed by 9 executives with a total tenure of roughly 40 years, averaging almost 4.0 years of service per executive, having 1.89 employees per reported executive. Recap of Traws Pharma's management performance can provide insight into the venture performance.
Traws |
Traws Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.5251) % which means that it has lost $0.5251 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.9652) %, meaning that it created substantial loss on money invested by shareholders. Traws Pharma's management efficiency ratios could be used to measure how well Traws Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.88 in 2024. Return On Capital Employed is likely to climb to -1.43 in 2024. At this time, Traws Pharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 1.9 M in 2024, whereas Non Currrent Assets Other are likely to drop 855.00 in 2024.Common Stock Shares Outstanding is likely to drop to about 15.7 M in 2024
Traws Pharma Workforce Comparison
Traws Pharma is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 91,497. Traws Pharma adds roughly 17.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Traws Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Traws Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Traws Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Traws Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nikolay Savchuk over a month ago Acquisition by Nikolay Savchuk of 885532 shares of Traws Pharma at 0.01 subject to Rule 16b-3 | ||
Redfield Robert over two months ago Acquisition by Redfield Robert of 97500 shares of Traws Pharma at 0.01 subject to Rule 16b-3 | ||
Greenwood Luba over three months ago Insider Trading | ||
Nikolay Savchuk over three months ago Acquisition by Nikolay Savchuk of 4801 shares of Traws Pharma subject to Rule 16b-3 | ||
Guerin Mark Patrick over six months ago Disposition of 5500 shares by Guerin Mark Patrick of Traws Pharma subject to Rule 16b-3 | ||
Guerin Mark Patrick over six months ago Acquisition by Guerin Mark Patrick of 5500 shares of Traws Pharma subject to Rule 16b-3 | ||
Dukes Iain D. over six months ago Acquisition by Dukes Iain D. of 3802890 shares of Traws Pharma at 0.07 subject to Rule 16b-3 | ||
Nikolay Savchuk over six months ago Insider Trading |
Traws Pharma Notable Stakeholders
A Traws Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Traws Pharma often face trade-offs trying to please all of them. Traws Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Traws Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Werner Cautreels | CEO Director | Profile | |
| DPHIL MA | Executive Chairman | Profile | |
| Steven MD | President Oncology | Profile | |
| Nikolay Savchuk | COO Director | Profile | |
| Robert MD | Acting Officer | Profile | |
| Mark CPA | Chief Officer | Profile | |
| Victor MD | Chief Oncology | Profile | |
| Charles Pauza | Chief Virology | Profile | |
| C Pauza | Chief Virology | Profile |
About Traws Pharma Management Performance
The success or failure of an entity such as Traws Pharma often depends on how effective the management is. Traws Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Traws management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Traws management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.84) | (0.88) | |
| Return On Capital Employed | (1.51) | (1.43) | |
| Return On Assets | (0.84) | (0.88) | |
| Return On Equity | (1.78) | (1.86) |
Please note, the imprecision that can be found in Traws Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Traws Pharma. Check Traws Pharma's Beneish M Score to see the likelihood of Traws Pharma's management manipulating its earnings.
Traws Pharma Workforce Analysis
Traditionally, organizations such as Traws Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Traws Pharma within its industry.Traws Pharma Manpower Efficiency
Return on Traws Pharma Manpower
| Revenue Per Employee | 13.3K | |
| Revenue Per Executive | 25.1K | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 2.1M | |
| Working Capital Per Employee | 790.6K | |
| Working Capital Per Executive | 1.5M |
Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.